My tumor marker Chromogranin A elevated to 518 7 days after 1st vaccine and further elevated to 648 within 2 weeks of second vaccine; peri hilar and mediastinal lymphadenopathy; This is a spontaneous report received from contactable reporter(s) (Other HCP). The reporter is the patient.  A 59-year-old female patient (not pregnant) received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) at the age of 59 years as dose 2, single for covid-19 immunisation. The patient was not pregnant at time of vaccination. Relevant medical history included: "other medical history: carcinoid cancer" (unspecified if ongoing), notes: other medical history: carcinoid cancer; "BRCA1" (unspecified if ongoing), notes: other medical history: BRCA1; "other medical history: breast cancer" (unspecified if ongoing), notes: other medical history: breast cancer; "other medical history: thyroid cancer" (unspecified if ongoing), notes: other medical history: thyroid cancer; "other medical history: colon cancer" (unspecified if ongoing), notes: other medical history: colon cancer; "known allergies: Sulfa" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Bnt162b2 (dose number=1, vaccine location=Right arm, Reaction: My tumour marker Chromogranin A elevated to 518 7 days after 1st vaccine), administration date: 28Dec2020, for covid-19 immunization, reaction(s): "My tumor marker Chromogranin A elevated to 518 7 days after 1st vaccine". The following information was reported: TUMOUR MARKER INCREASED (non-serious) with onset 06Jan2021, outcome "recovering", described as "My tumor marker Chromogranin A elevated to 518 7 days after 1st vaccine and further elevated to 648 within 2 weeks of second vaccine"; LYMPHADENOPATHY (non-serious) with onset 06Jan2021, outcome "recovering", described as "peri hilar and mediastinal lymphadenopathy". The events "my tumor marker chromogranin a elevated to 518 7 days after 1st vaccine and further elevated to 648 within 2 weeks of second vaccine" and "peri hilar and mediastinal lymphadenopathy" were evaluated at the physician office visit. Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of tumour marker increased, lymphadenopathy.  Additional information: Patient stated her tumor marker Chromogranin A elevated to 518 7 days after 1st vaccine and further elevated to 648 within 2 weeks of second vaccine. Subsequent PET scan showed peri hilar and mediastinal lymphadenopathy. Bronchoscopy with biopsy of nodes showed reactive lymphocytes. 3 months after vaccine, tumor marker still elevated but down to 125. She had a history of carcinoid cancer but no active disease. The Facility where the most recent COVID-19 vaccine was administered was hospital. The adverse event result in doctor or other healthcare professional office/clinic visit. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient received medications within 2 weeks of vaccination. Patient did not received any other vaccines within 4 weeks prior to the COVID vaccine. The patient received other medications within 2 weeks of vaccination.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.